AI analysis of chest X-rays to identify people at high lung cancer risk for CT screening
Official title: Deep Learning Using Routine Chest X-Rays and Electronic Medical Record Data to Identify High Risk Patients for Lung Cancer Screening CT
Run by Massachusetts General Hospital · NCT06910956 · Data updated 2026-11-12
This project tests whether an AI that flags people at high 6-year lung cancer risk from chest X-rays can increase CT screening in adults 50–77 who currently or formerly smoked.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 77 Years |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | May 20, 2025 |
| Main results expected | July 1, 2027 |
| Study ends | July 1, 2027 |
| Registry record updated | May 11, 2026 |
| Trial ID | NCT06910956 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are 50–77‑year‑old current or former smokers who have had a PA chest X‑ray within the past two years and a scheduled outpatient visit at the participating clinic.
✕Probably not a fit
People with recent chest CT, active symptoms or history of lung cancer, or those outside the age and smoking criteria are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial randomizes eligible outpatients to usual care or to an intervention where the CXR-LC AI analyzes recent PA chest X‑rays and alerts providers when a patient has high 6‑year lung cancer risk. When alerted, providers are prompted to discuss lung cancer screening CT eligibility; patients flagged as high-risk who do not meet Medicare/USPSTF pack‑year or quit‑date criteria may be offered research CT. Eligible participants are 50–77‑year‑old current or former smokers with a PA chest radiograph within the past two years and a scheduled outpatient visit, while those with recent chest CT, signs/symptoms of lung cancer, or prior lung cancer are excluded. The primary outcome is whether CT screening participation increases within 6 months after the baseline visit.
Why it matters
Potential benefit: If successful, the tool could increase screening referrals and help detect lung cancers earlier by prompting clinicians to discuss CT screening.
How similar studies have gone: Retrospective studies suggest chest X‑ray AI can stratify lung cancer risk, but prospective trials using provider alerts to increase screening participation remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Major Inclusion Criteria: * Scheduled outpatient appointment with participating provider. * 50- to 77-year-old who currently or formerly smoked, to include persons potentially eligible for lung screening based on Medicare guidelines. * Recent (within 2 years) PA chest radiograph. Exclusion Criteria: • History or signs/symptoms of lung cancer. Recent (within 2 years) chest CT. Clinical indication for chest CT beyond lung cancer screening.
Where it's running
-
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Study coordinator: Michael T Lu, MD, MPH
- Email: mlu@mgh.harvard.edu
- Phone: 617-726-1255
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.